Compare PSEC & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSEC | PRCT |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2021 |
| Metric | PSEC | PRCT |
|---|---|---|
| Price | $2.77 | $25.59 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $2.50 | ★ $35.44 |
| AVG Volume (30 Days) | ★ 4.2M | 1.2M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 19.22% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | N/A | $24.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $2.45 | $19.35 |
| 52 Week High | $3.77 | $64.89 |
| Indicator | PSEC | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 59.75 | 53.28 |
| Support Level | $2.72 | $22.81 |
| Resistance Level | $2.82 | $27.08 |
| Average True Range (ATR) | 0.07 | 1.21 |
| MACD | 0.03 | 0.25 |
| Stochastic Oscillator | 63.53 | 83.94 |
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.